EP3958826A1 - Composition déodorante ou antiperspirante contenant un donneur de calcium ou de lactate - Google Patents

Composition déodorante ou antiperspirante contenant un donneur de calcium ou de lactate

Info

Publication number
EP3958826A1
EP3958826A1 EP20721482.6A EP20721482A EP3958826A1 EP 3958826 A1 EP3958826 A1 EP 3958826A1 EP 20721482 A EP20721482 A EP 20721482A EP 3958826 A1 EP3958826 A1 EP 3958826A1
Authority
EP
European Patent Office
Prior art keywords
acid
composition
calcium
deodorant
antiperspirant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20721482.6A
Other languages
German (de)
English (en)
Inventor
Anne LIEBICH
Michael Urban
Sandra TIEDEMANN
Dorothea Schweiger
Wiebke Krieger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP3958826A1 publication Critical patent/EP3958826A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the present invention particularly relates to mild cosmetic compositions for application under the human armpit.
  • Sweat is called a sweat from the skin of humans via so-called sweat glands
  • secreted watery secretion There are three types of sweat glands in the skin, namely apocrine, eccrine and apoecrine sweat glands (Int J Cosmet Sci. 2007 Jun;
  • the eccrine sweat glands are practically distributed over the entire body and can produce considerable amounts of a clear, odorless secretion that is more than 99% water.
  • the apocrine sweat glands occur only in the hairy areas of the body of the armpit and genital region as well as on the nipples. They produce small amounts of a milky secretion that contains proteins and lipids.
  • Sweating also known as perspiration, is an effective mechanism for releasing excess heat and thus regulating body temperature.
  • the sweat - especially the secretion of the apocrine sweat glands - is also assigned a signaling effect via the sense of smell.
  • the apocrine sweat plays particularly in connection with the emotional or stress-related
  • Body odor occurs when the fresh sweat, which is odorless, is broken down by microorganisms such as staphylococci and corynebacteria.
  • deodorant and antiperspirant. Rather - especially in German-speaking countries - products for use in the armpit area are generally referred to as "deodorants”. This happens regardless of the question of whether there is also an antiperspirant effect.
  • Antiperspirants are antiperspirants that are supposed to prevent the secretion of sweat at all.
  • Aluminum salts are used as active antiperspirant ingredients. These inhibit the flow of sweat by clogging the ducts of the sweat glands, as they precipitate on site together with the skin's own proteins and thus lead to so-called plugs.
  • odor improvers In contrast to antiperspirants, pure deodorants do not actively influence the sweat secretion, but only control or influence the body or armpit odor (odor improvers).
  • the odor of sweat consists largely of branched-chain fatty acids that are released from odorless sweat by bacterial enzymes.
  • Classic deodorant active ingredients counteract this, for example by reducing the growth of bacteria. It is also possible to have a
  • a product is referred to as an antiperspirant or an antiperspirant cosmetic composition if it comprises an antiperspirant ingredient in a sweat-regulating concentration.
  • Sweat regulation as described, is usually from one, for example, when using aluminum salts
  • a product is called a deodorant or deodorant cosmetic
  • Composition refers to when it does not contain aluminum salts and / or does not contain any other antiperspirant active ingredient and thus does not actively obstruct the flow of sweat, the product containing agents which improve odor and the product is used on the underarm skin.
  • a first object of the invention was therefore to make the components of bovine milk relevant for skin care accessible in deodorant and / or antiperspirant compositions.
  • deodorant or antiperspirant compositions can lead to skin irritation or skin irritation in sensitive people, or also when used after shaving. These effects can be measured, for example, using inflammatory markers that have a changed regulation in the event of skin irritation, skin inflammation and / or skin irritation.
  • lipids preferably selected from the group of triglycerides; and c) optionally lactose.
  • a milk essence is understood to mean a composition of the components contained in the milk essence.
  • Another object of the invention is a deodorant and / or
  • An antiperspirant composition comprising
  • lipids preferably selected from the group of triglycerides and c) optionally lactose.
  • Another object of the invention comprises a cosmetic composition for use under the armpits
  • one or more lipids preferably selected from the group of triglycerides
  • the invention also relates to the use of at least one calcium donor and / or at least one lactate donor in a cosmetic composition containing one or more lipids, preferably selected from the group of triglycerides, at least one deodorant active ingredient that is not an aluminum salt, and / or at least one antiperspirant active ingredient ,
  • Another object of the invention is a composition
  • a composition comprising
  • one or more lipids preferably selected from the group of triglycerides
  • the invention also relates to the use of the essence according to the invention or the respective composition according to the invention for reducing skin irritations and / or skin irritations; especially for reducing skin irritation caused by shaving.
  • compositions according to the invention have been shown to reduce various proinflammatory markers (MIF, I L-1 a) and thus contribute to the anti-irritative or anti-inflammatory effect of the respective composition and thus to the improved care properties.
  • MIF proinflammatory markers
  • Normal conditions carried out.
  • the term “normal conditions” means 20 ° C, 1013 hPa and a relative humidity of 50%.
  • viscosity values are given in this disclosure, then all values relate to a measurement at 25 ° C in a 150 ml wide neck bottle (VWR no .: 807-001) using Rheomat R 123 from proRheo.
  • the Rheomat R 123 from proRheo GmbH is a
  • Rotational viscometer d. H. a measuring body rotates in the substance to be measured. The force is measured that is required to make the measuring body rotate in the sample at a specified speed. The viscosity is calculated from this torque, the speed of the measuring body and the geometric dimensions of the measuring system used.
  • the measuring body no.1 (item no. 200 0191), suitable for a
  • Viscosity range up to 10,000 [mPa-s], speed range 62.5 min 1 , used.
  • Compositions according to the invention advantageously contain a calcium salt as calcium donor.
  • This calcium salt is preferably a salt of a carboxylic acid.
  • Calcium salts of carboxylic acids to be chosen advantageously are salts of fatty acids having 16 to 22 carbon atoms, especially advantageously calcium stearate, salts of hydroxycarboxylic acids, especially of lactic acid or citric acid, and the salt of pantothenic acid. Calcium pantothenate is particularly preferred. It is also possible to use inorganic calcium salts, preferably calcium chloride according to the invention.
  • a calcium salt of phosphoric acid can advantageously be chosen as the calcium donor. If, in one embodiment, calcium lactate is used as an additional calcium donor, then this substance functions simultaneously as a calcium and lactate donor.
  • the composition or essence according to the invention advantageously comprises a lactate donor, which is advantageously a salt of lactic acid.
  • a lactate donor which is advantageously a salt of lactic acid.
  • Sodium lactate, calcium lactate, magnesium lactate, potassium lactate, ammonium lactate, menthyl lactate, lauryl lactate and / or C12-15 alkyl lactate are preferred.
  • Sodium lactate is particularly preferred.
  • composition or essence contains calcium panthotenate as the calcium donor and sodium lactate as the lactate donor.
  • the total proportion of components a) in the respective composition according to the invention is from 0.05 to 3% by weight, preferably from 0.1 to 2.5% by weight and particularly preferably from 0.1 to 0.5 wt .-%, based on the
  • the lipids are advantageously selected from the group of triglycerides which have been obtained by esterifying glycerol with the fatty acids butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, myristoleic acid, palmitic acid, stearic acid, oleic acid, linoleic acid and / or linolenic acid.
  • the properties of the essence according to the invention or the compositions according to the invention could be surprisingly improved by adding the substance known under the INCI name Caprylic / Capric Triglyceride as a lipid.
  • the essence or the compositions according to the invention thus advantageously comprises caprylic / capic triglycerides as lipid.
  • caprylic / capric triglyceride a significantly faster absorption of the essence or composition according to the invention is also achieved.
  • composition according to the invention containing 20% by weight of caprylic / capric triglycerides, based on the total weight of the composition, to the skin in an area of 5 ⁇ 5 cm and, after one minute, with the supernatants that were not absorbed Blotting paper were included.
  • the composition according to the invention was surprising Composition absorbed by the skin much faster. The blotting paper was less damp.
  • the absolute amount of lipids, in particular of caprylic / capric triglycerides, depends on the composition according to the invention used in each case and its dosage form, but can generally advantageously be selected in the range from 1 to 35% by weight, based on the total weight of the respective composition.
  • compositions according to the invention or the essence according to the invention can furthermore advantageously contain lactose, in particular lactose monohydrate.
  • lactose in particular lactose monohydrate.
  • the proportion of lactose or lactose monohydrate is advantageously from 0.1 to 2% by weight, based on the total weight of the respective composition.
  • compositions according to the invention can furthermore advantageously contain at least one deodorant active ingredient that is not an aluminum salt.
  • the deodorant active ingredient is selected from the group consisting of ethylhexylglycerol, butyloctanoic acid, polyquaternium-6, polyquaternium-16, octenidines and methyl phenylbutanol.
  • the proportion of ethylhexylglycerol is advantageously from 0.1 to 1% by weight, based on the total weight of the composition.
  • polyquaternium-6 is present, the proportion of polyquaternium-6 is advantageously from 1 to 3% by weight, based on the total weight of the composition.
  • polyquaternium-16 contains polyquaternium-16, the proportion of polyquaternium-16 is advantageously from 1 to 3% by weight, based on the total weight of the composition.
  • Aluminum salts such as aluminum chloride AICI 3 , aluminum sulfate AI 2 (S0 4 ) 3
  • the antiperspirant active ingredient contains at least one aluminum-zirconium salt.
  • aluminum / zirconium trichlorohydrex glycine [AI 4 ZG (OH) I 3 OI 3 ] XH 2 0 X Gly), aluminum / zirconium tetrachlorohydrex glycine ([AI 4 Zr (OH) i 2 CI 4 ] x H 2 0 x Gly), aluminum / zirconium pentachlorohydrex glycine ([AI 8 Zr (OH) 23 Cl5] x H 2 0 x Gly), aluminum / zirconium octachlorohydrex glycine ([AI 8 ZG (OH) 2O OI 8 ] XH 2 0 x Gly) and the glycine-free aluminum / zirconium salts.
  • Aluminum / zirconium tetrachlorohydrex glycine is particularly
  • the respective composition is characterized in that it has at least one further constituent selected from the list of histidines; preferably Histidine HCl; Threonines, lysines; preferably lysine HCl, arginine, serine, glycogen, alanine and glutamic acid is contained, the total proportion of these constituents advantageously being less than 1% by weight, based on the total weight of the respective composition.
  • the respective composition is characterized in that it has at least one further component selected from the list Octyldodecanol,
  • the essence or composition according to the invention can also advantageously contain vitamins or their derivatives.
  • vitamins or their derivatives Preferably selected from those that are contained in bovine milk.
  • Tocopheryl acetate (derivative vitamin E), sodium ascorbyl phosphate (derivative vitamin C) and calcium pantothenate (derivative vitamin B5) are particularly advantageously selected.
  • the proportion of tocopheryl acetate is advantageously from 0.01 to 1% by weight, based on the total weight of the composition.
  • the proportion of sodium ascorbyl phosphate is advantageously from 0.01 to 1% by weight, based on the total weight of the respective composition.
  • compositions according to the invention can furthermore advantageously contain sodium ascorbyl phosphate.
  • the proportion of sodium ascorbyl phosphate is advantageously from 0.01 to 1% by weight, based on the total weight of the respective composition.
  • composition according to the invention and / or the essence according to the invention preferably contains no proteins and / or no protein hydrolysates.
  • the composition according to the invention is packaged together with a propellant gas in a pressure container with a dispensing valve.
  • a propellant gas in a pressure container with a dispensing valve.
  • Mixtures of propane, butane and / or isobutane are used as propellant gases.
  • the weight fraction of the composition in the pressure vessel is advantageously from 10 to 50% by weight, preferably from 15 to 30% by weight, based on the total weight of the composition and propellant gas.
  • the invention also relates to a cosmetic product comprising a pressure container with a dispensing valve
  • a composition according to the invention as described above, and b) propellant gas, in particular propane, n-butane and / or isobutane,
  • the weight fraction of the composition in the pressure vessel from 10 to 50 wt .-%, preferably 15 to 30 wt .-%, based on the
  • a composition according to the invention which is suitable for being filled into a pressure vessel together with propellant gas and which is sprayed out of this pressure vessel via a valve advantageously has caprylic / capric triglyceride in a proportion of 5 to 30% by weight, preferably 7 to 27% Wt .-% and particularly preferably 10 to 25 wt .-% based on the total weight of the cosmetic composition.
  • such a composition according to the invention is advantageously characterized in that the proportion of water in the composition is less than 1% by weight based on the total weight of the composition.
  • composition according to the invention contains an antiperspirant active ingredient
  • the proportion of the antiperspirant active ingredient, in particular the aluminum salt and particularly preferably the aluminum salts with the formula [Al 2 (OH) mCln], where m + n 6, is from 10 to 50% by weight, preferably from 15 to 40% by weight, based on the total weight of the composition.
  • the proportion of the deodorant active ingredient is from 0.1 to 1% by weight, preferably from 0.2 to 0.5% by weight, of Butyloctanoic acid, from 0.1 to 1 wt .-%, preferably from 0.2 to 0.5 wt .-% and of ethylhexylglycerol, from 0.1 to 2 wt .-%, preferably from 0.2 to 1 wt. -% based on the total weight of the composition.
  • compositions according to the invention also advantageously contain isopropyl palmitate and / or isopropyl myristate. If isopropyl palmitate and / or isopropyl myristate are contained, the total proportion of these substances is advantageously from 4 to 35% by weight based on the total weight of the composition.
  • Such compositions according to the invention are furthermore advantageously characterized in that they contain an organically modified clay material. Examples of such organically modified clay materials are the preferred substances disteardimonium hectorite and stearalkonium bentonite. The proportion of these organically modified clay materials is advantageously from 1% by weight to 5% by weight based on the total weight of the composition.
  • propylene carbonate is additionally contained as an activator for the clay materials, the proportion of propylene carbonate advantageously being from 0.5 to 1.5% by weight based on the total weight of the composition.
  • compositions according to the invention show a particularly effective anti-inflammatory or anti-inflammatory effectiveness and at the same time are felt to be particularly mild to the skin.
  • compositions that are packaged in a pressure vessel with propellant gas and dispensed from the pressure vessel via a dispensing valve are possible.
  • composition according to the invention is applied directly to the skin in the form of an oil in water emulsion. It can be applied using a conventional deodorant roller.
  • Such a composition according to the invention which is in the form of an O / W emulsion, advantageously contains caprylic / capric triglycerides in a proportion of 2 to 4% by weight, based on the total weight of the composition.
  • composition according to the invention which is in the form of an O / W emulsion, advantageously contains at least one nonionic emulsifier with an HLB value in the range from 3 to 6.
  • lipophilic emulsifiers normally stabilize water-in-oil emulsions.
  • advantageous compositions in the form of O / W emulsions are characterized in that at least one nonionic emulsifier with an HLB value in the range from 3 to 6 in a total amount of 1.8 to 3.8 wt .-%, based on the
  • Nonionic Emulsifiers with an HLB value in the range from 3 to 6 are selected from steareth, ceteth, myristeth, laureth, trideceth, araffleth and beheneth, each with 1 to 4 ethylene oxide units per molecule.
  • compositions of this type which are in the form of an O / W emulsion, are advantageously characterized in that they contain at least one nonionic emulsifier with an HLB value in the range from 12 to 18, the total proportion of these emulsifiers advantageously being from 1.4 to 3 , 7% by weight based on the total weight of the composition.
  • Preferred nonionic emulsifiers with an HLB value in the range from 12-18 are Steareth-15, Steareth-20, Steareth-21, Araezeth-20, Araezeth-21, Beheneth-20, Beheneth-21, Ceteth-20, Ceteth-30 , Ceteth-15 and Myristeth-15. Steareth-21 is particularly preferred.
  • Polyquaternium-16 is selected as the deodorant active ingredient.
  • This is used in the composition according to the invention, which is present as an O / W emulsion, preferably in a proportion of 0.5 to 2% by weight, based on the total weight of the composition.
  • composition is preferred if it contains aluminum chlorohydrate as the antiperspirant active ingredient, the proportion of aluminum chlorohydrate advantageously being from 8% by weight to 18% by weight based on the total weight of the composition.
  • the proportion of water in this composition is advantageously from 70 to 80% by weight based on the total weight of the composition. If no antiperspirant active ingredient or no aluminum salt, in particular no aluminum chloride, and / or aluminum chlorohydrate is contained, it is further preferred if the proportion of water in the composition according to the invention is from 72 to 86% by weight, based on the total weight of the composition.
  • the composition according to the invention is in the form of a solid stick which, by abrasion, transfers the composition according to the invention to the skin.
  • the composition contains 12 to 30% by weight of one or more fatty alcohols, in particular stearyl alcohol, 0.5 to 5% by weight of tallow and 20 to 40% by weight of cyclomethicones, based on the total weight of the Composition, contains.
  • glyceryl stearate SE is additionally contained, the proportion of glyceryl stearate SE advantageously being from 0.3 to 1% by weight, based on the total weight of the composition.
  • caprylic / capric triglyceride is from 2 to 5% by weight, based on the total weight of the composition.
  • aluminum / zirconium tetrachlorohydrex glycine is contained as the antiperspirant active ingredient, the proportion of aluminum / zirconium tetrachlorohydrex glycine advantageously being 8 to 25% by weight, based on the total weight of the composition.
  • PPG-14 butyl ether is also included, the proportion of PPG-14 butyl ether preferably being from 4 to 22% by weight, particularly preferably from 12 to 18% by weight on the total weight of the composition.
  • compositions can comprise further ingredients, provided that these influence the stability and function of the composition.
  • Additional ingredients can include liquid perfume components, dyes or other nourishing ingredients.
  • Formulations A and C were each placed in a pressure vessel with a dispensing valve. Then the respective pressure vessel was filled with propellant gas.
  • the propellant gas mixture is composed of 20% by weight propane, 60% by weight n-butane and 20% by weight isobutane.
  • the weight ratio of the respective formulation to the propellant gas was 15% by weight to 85% by weight.
  • the protocol was adapted accordingly for testing mixtures.
  • the skin models were normally incubated in an incubator at 37 ° C, 5% CO 2. 3 skin models were used for each formulation, positive (0.1% SDS solution (sodium dodecyl sulfate)) and negative control (untreated control).
  • the amount of proinflammatory marker IL1 alpha was examined on 5 test persons 24 hours after application to the skin.
  • the detection of the IL-1 alpha in pg / ml was performed using the commercially available kit Quantikine ® ELISA Human IL-1 alpha / IL-1 F 1 (Item No. DLA50) from R & D Systems, Inc. USA.
  • the IL1 alpha results were normalized to the total amount of protein pg IL1 alpha / pg total protein.
  • IL1 alpha is an epidermal cytokine which has pro-inflammatory effects d. H. it is responsible for the formation / promotion of inflammation. It is expressed both by keratinocytes and by immune cells such as macrophages, neutrophils. The importance of IL1 alpha in inflammation / inflammatory processes and skin diseases is clearly described in scientific publications:
  • MIF Macrophage migration inhibitory factor
  • MIF Macrophage migration inhibitory factor
  • compositions according to the invention thus have an anti-inflammatory effect. Again, the anti-inflammatory effects of bovine milk are surpassed.
  • flakes of skin were obtained by shaving, by shaving defined areas on the forearm dry (10x down, 5x up). Every 2-3 razor marks the razor would tap out.
  • the razor was washed out with water at the end and the Flakes of skin collected in phosphate buffer. The samples were frozen for storage. After thawing and mixing, the samples were treated with ultrasound for 30 minutes at room temperature and then centrifuged. Lactate or calcium was detected from the supernatant.
  • the calcium was determined from skin rinses which were carried out 24 hours after application. All areas on the subjects' forearms were shaved.
  • the lactate was determined from skin rinses 4.5 hours after application
  • Lactate detection was carried out using a commercial colorimetric assay (Lactate Kit Reagent 10x10mL (Catalog No. 735-10) and Lactate Standard solution 40 mg / dl (Catalog No. 826-10) from Trinity Biotech, Wicklow, Ireland). 5 test persons participated per sample, so that the mean values are shown in Figure 6. It turns out that, particularly when using formulation A, a heavy lactate deposition was detectable. The deposit was stronger than with conventional whole milk with 3.5% fat.
  • Calcium was also determined from D-Squames (DSQ) after product application. For this purpose, calcium was detected from 3 D squames (mean value from all 3 D squames, over 2 test subjects). The DSQs were pulled 4 h after application (treatment: (a) AT product with essence according to the invention, (b) competitor product without essence, (c) whole milk 3.5% fat, control untreated). Once the determination was carried out with shaving and once without shaving. Calcium was detected using m-X-ray fluorescence spectroscopy. The raw data determined have no dimension such as ppm or g / kg, but only reflect the measured signal intensities (the higher the intensity, the higher the concentration of calcium in the skin particles on the D-Squames). The measurement data obtained are shown in Figure 7.
  • the product with the essence according to the invention showed almost the same signal intensity as when whole milk 3.5% fat was applied.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

Composition cosmétique ou essence pour l'utilisation sous les aisselles, pour une composition déodorante et/ou antiperspirante comprenant a) au moins un donneur de calcium et/ou de lactate ; b) un ou plusieurs lipides, de préférence choisis dans le groupe des triglycérides, les lipides choisis dans le groupe des triglycérides qui ont été obtenus par l'estérification de glycérine avec les acides gras acide butyrique, acide caproique, acide caprylique, acide caprique, acide laurique, acide myristique, acide myristoléique, acide palmitique, acide stéarique, acide oléïque, acide linoléique et/ou acide linolénique étant particulièrement préférés ; et c) facultativement du lactose.
EP20721482.6A 2019-04-23 2020-04-20 Composition déodorante ou antiperspirante contenant un donneur de calcium ou de lactate Withdrawn EP3958826A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102019205767.5A DE102019205767A1 (de) 2019-04-23 2019-04-23 Deodorant- oder Antitranspirantzusammensetzung
PCT/EP2020/060950 WO2020216696A1 (fr) 2019-04-23 2020-04-20 Composition déodorante ou antiperspirante contenant un donneur de calcium ou de lactate

Publications (1)

Publication Number Publication Date
EP3958826A1 true EP3958826A1 (fr) 2022-03-02

Family

ID=70465009

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20721482.6A Withdrawn EP3958826A1 (fr) 2019-04-23 2020-04-20 Composition déodorante ou antiperspirante contenant un donneur de calcium ou de lactate

Country Status (3)

Country Link
EP (1) EP3958826A1 (fr)
DE (1) DE102019205767A1 (fr)
WO (1) WO2020216696A1 (fr)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW211523B (en) * 1992-06-29 1993-08-21 Amerchol Corp Hydroxylated milk glycerides
US5605681A (en) 1994-09-16 1997-02-25 The Proctor & Gamble Company Mild gel deodorant composition containing soap, polymeric hydrogel forming polymer and high level of water
US5968489A (en) 1998-05-01 1999-10-19 The Procter & Gamble Company Antiperspirant composition containing 1,2-hexanediol
US6083493A (en) 1999-08-24 2000-07-04 The Procter & Gamble Company Antiperspirant compositions containing isopropyl glycerol ether
DE10042710A1 (de) * 2000-08-31 2002-03-28 Peter Keller Dermatologische oder kosmetische Zubereitung auf der Basis von Säugetierbutter
DE10137901A1 (de) * 2001-06-01 2002-12-05 Henkel Kgaa Arylsulfatase-Inhibitoren in Deodorantien und Antitranspirantien
US20050255059A1 (en) * 2004-05-10 2005-11-17 Oblong John E Personal care compositions and methods regulating mammalian hair growth
DE102007022694A1 (de) * 2007-05-11 2008-11-13 Humana Milchunion Eg Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme
DE102011003331A1 (de) * 2011-01-28 2012-08-02 Henkel Ag & Co. Kgaa Hautnährende Antitranspirant-Zusammensetzungen
DE102011018924A1 (de) * 2011-04-28 2012-10-31 Tunap Industrie Chemie Gmbh & Co. Produktions Kg OW-Emulsionskonzentrat, Verfahren zu dessen Herstellung und dieses enthaltendes Hautkosmetikum
WO2013167220A1 (fr) * 2012-05-08 2013-11-14 Merck Patent Gmbh Utilisation de dérivés de cyclohexanol-éther à propriétés antimicrobiennes
DE102015202971A1 (de) * 2015-02-19 2015-12-03 Henkel Ag & Co. Kgaa Körperreinigungsmittel enthaltend eine hautpflegende Pflanzenmilch

Also Published As

Publication number Publication date
WO2020216696A1 (fr) 2020-10-29
DE102019205767A1 (de) 2020-10-29

Similar Documents

Publication Publication Date Title
RU2668129C2 (ru) Полужидкая эмульсия масло-в-воде, содержащая смесь неионогенных сурфактантов, водорастворимый полисахарид и воск, содержащий по меньшей мере один сложный эфир
RU2712152C1 (ru) Композиции для уменьшения раздражения за счет синергетического действия таурина и алоэ и связанные с ними способы
WO2013075826A2 (fr) Utilisation de caprylates/caprates d'isosorbide dans des déodorants et des anti-transpirants
AU2014361780B2 (en) Exfoliative hair retention-promoting formulation
JP2010138154A (ja) エージング対応用の皮膚外用剤
JP2004536126A (ja) 長期冷却作用を有する化粧品もしくは皮膚科学的調製物
JPS62292710A (ja) 皮膚化粧料
WO2022069738A1 (fr) Composition pour traiter les cheveux, le cuir chevelu et la peau
EP0375082B1 (fr) Composition cosmétique
EP1962777A1 (fr) Action longue duree amelioree d'antitranspirants
EP3958826A1 (fr) Composition déodorante ou antiperspirante contenant un donneur de calcium ou de lactate
EP3969126B1 (fr) Composition déodorante
JPH0678214B2 (ja) 頭髪化粧料
EP2934437B1 (fr) Utilisation de sels d'aluminium pour lutter contre la transpiration due au stress
EP4142685A1 (fr) Liquide ionique en tant qu'anti-transpirant
WO2023042911A1 (fr) Composition anti-odeur des aisselles
WO2015022315A2 (fr) Préparations déodorantes et/ou antitranspirantes contenant des accepteurs de michaël polycycliques
Rähse Design of skin care products
JPS62226910A (ja) 皮膚化粧料
JP2010059115A (ja) スキンケア方法
JP5768114B2 (ja) エージング対応用の皮膚外用剤の製造方法
Giovanniello Antiperspirants and deodorants
EP4011361A1 (fr) Composition cosmétique topique, utilisation de cette composition et tonique pour application faciale
WO2023194557A1 (fr) Composition pour le traitement de la peau
JP6469344B2 (ja) 皮膚化粧料

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220614